Trial Profile
Docetaxel +/- AZD6244 in Melanoma - A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Docetaxel
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms DOC-MEK
- 10 Jul 2020 This trial is completed (Global End Date: 20 Feb 2020), according to European Clinical Trials Database record.
- 16 Dec 2019 Results published in the British Journal of Cancer
- 03 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.